newsfilter
← Latest News
GlobeNewswire·

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and